Clinical implications of understanding the association between oxidative stress and pediatric NAFLD

References

• Richter K, Kietzmann T. Reactive oxygen species and fibrosis: further evidence of a significant liaison. Cell Tissue Res. 2016;365(3):591–605.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554.
   PubMed Web of Science ®Google Scholar
• Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417(1):1–13.
   PubMed Web of Science ®Google Scholar
• Gusdon AM, K-X S, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev. 2014;2014:637027.
   PubMed Web of Science ®Google Scholar
• Kim H, Mendez R, Zheng Z, et al. Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor alpha to regulate metabolic hormone FGF21. Endocrinology. 2014;155(3):769–782.
   PubMed Web of Science ®Google Scholar
• Al-Serri A, Anstee QM, Valenti L, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol. 2012;56(2):448–454.
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15(4):249–274.
   PubMed Web of Science ®Google Scholar
• Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148(6):1145–1159.
   PubMed Web of Science ®Google Scholar
• Manganas P, MacPherson L, Tokatlidis K. Oxidative protein biogenesis and redox regulation in the mitochondrial intermembrane space. Cell Tissue Res. 2016. Epub ahead of print DOI:10.1007/s00441-016-2488-5
   PubMed Web of Science ®Google Scholar
• Yin X, Zheng F, Pan Q, et al. Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening. J Mol Endocrinol. 2015;55(3):169–181.
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999;31(3):430–434.
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. J Am Med Assoc. 1999;282(17):1659–1664.
   PubMed Web of Science ®Google Scholar
• Dasarathy S, Yang Y, McCullough AJ, et al. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23(5):382–388.
   PubMed Web of Science ®Google Scholar
• Pellegrino MW, Nargund AM, Haynes CM. Signaling the mitochondrial unfolded protein response. Biochim Biophys Acta - Mol Cell Res. 2013;1833(2):410–416.
   PubMed Web of Science ®Google Scholar
• Hyötyläinen T, Jerby L, Petäjä EM, et al. Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nat Commun. 2016;7:8994.
   PubMed Web of Science ®Google Scholar
• Sunny NE, Kalavalapalli S, Bril F, et al. Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab. 2015;309(4):E311–9.
   PubMed Web of Science ®Google Scholar
• Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21(5):739–746.
   PubMed Web of Science ®Google Scholar
• Satapati S, Kucejova B, Duarte JAG, et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest. 2015;125(12):4447–4462.
   PubMed Web of Science ®Google Scholar
• Hautekeete ML, Degott C, Benhamou JP. Microvesicular steatosis of the liver. Acta Clin Belg. 1990;45(5):311–326.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Flichman D, Scian R, et al. Mitochondrial genome architecture in non-alcoholic fatty liver disease. J Pathol. 2016;240(4):437–449.
   PubMed Web of Science ®Google Scholar
• Mehta R, Jeiran K, Koenig AB, et al. The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). BMC Med Genet. 2016;17(1):63.
   PubMed Web of Science ®Google Scholar
• Schröder T, Kucharczyk D, Bär F, et al. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. Mol Metab. 2016;5(4):283–295.
   PubMed Web of Science ®Google Scholar
• Begriche K, Massart J, Robin MA, et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58(4):1497–1507.
   PubMed Web of Science ®Google Scholar
• Pérez-Carreras M, Del Hoyo P, Martín M, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38(4):999–1007.
   PubMed Web of Science ®Google Scholar
• Paradies G, Petrosillo G, Paradies V, et al. Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease. Cell Calcium. 2009;45(6):643–650.
   PubMed Web of Science ®Google Scholar
• Olsen RKJ, Cornelius N, Gregersen N. Redox signalling and mitochondrial stress responses; lessons from inborn errors of metabolism. J Inherit Metab Dis. 2015;38(4):703–719.
   PubMed Web of Science ®Google Scholar
• Moon KH, Hood BL, Kim BJ, et al. Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology. 2006;44(5):1218–1230.
   PubMed Web of Science ®Google Scholar
• Sheldon RD, Padilla J, Jenkins NT, et al. Chronic NOS inhibition accelerates NAFLD progression in an obese rat model. Am J Physiol Gastrointest Liver Physiol. 2015;308(6):G540–9.
   PubMed Web of Science ®Google Scholar
• Valerio A, Cardile A, Cozzi V, et al. TNF-α downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest. 2006;116(10):2791–2798.
   PubMed Web of Science ®Google Scholar
• Ploumi C, Daskalaki I, Tavernarakis N. Mitochondrial biogenesis and clearance: A balancing act. Febs J. 2016; Epub ahead of print. 10.1111/febs.13820
   PubMed Web of Science ®Google Scholar
• Fedorowicz MA, De Vries-Schneider RLA, Ru’b C, et al. Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy. EMBO Rep. 2014;15(1):86–93.
   PubMed Web of Science ®Google Scholar
• Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biohys Acta. 2001;1813(7):1269–1278.
   Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–273.
   PubMed Web of Science ®Google Scholar
• Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond). 2004;106(3):261–268.
   PubMed Web of Science ®Google Scholar
• Haque JA, McMahan RS, Campbell JS, et al. Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Lab Invest. 2010;90(12):1704–1717.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Lavine JE, Wilson LA, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology. 2016;151(6):1141–1154.
   PubMed Web of Science ®Google Scholar
• Theurey P, Tubbs E, Vial G, et al. Mitochondria-associated endoplasmic reticulum membranes allow adaptation of mitochondrial metabolism to glucose availability in the liver. J Mol Cell Biol. 2016;8(2):129–143.
   PubMed Web of Science ®Google Scholar
• Pagliassotti MJ, Kim PY, Estrada AL, et al. Endoplasmic reticulum stress in obesity and obesity-related disorders: an expanded view. Metabolism. 2016;65(9):1238–1246.
   PubMed Web of Science ®Google Scholar
• Arruda AP, Pers BM, Parlakgül G, et al. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat Med. 2014;20(12):1427–1435.
   PubMed Web of Science ®Google Scholar
• Tubbs E, Theurey P, Vial G, et al. Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance. Diabetes. 2014;63(10):3279–3294.
   PubMed Web of Science ®Google Scholar
• Passos E, Ascensão A, Martins MJ, et al. Endoplasmic reticulum stress response in non-alcoholic steatohepatitis: the possible role of physical exercise. Metabolism. 2015;64(7):780–792.
   PubMed Web of Science ®Google Scholar
• Gonçalves IO, Passos E, Rocha-Rodrigues S, et al. Physical exercise prevents and mitigates non-alcoholic steatohepatitis-induced liver mitochondrial structural and bioenergetics impairments. Mitochondrion. 2014;15(1):40–51.
   PubMed Web of Science ®Google Scholar
• Guo R, Liong E, So K, et al. Beneficial mechanisms of aerobic exercise on hepatic lipid metabolism in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2015;14(2):139–144.
   PubMed Web of Science ®Google Scholar
• Li DJ, Fu H, Zhao T, et al. Exercise-stimulated FGF23 promotes exercise performance via controlling the excess reactive oxygen species production and enhancing mitochondrial function in skeletal muscle. Metabolism. 2016;65(5):747–756.
   PubMed Web of Science ®Google Scholar
• Finelli C, Tarantino G. Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol. 2012;18(46):6790–6800.
   PubMed Web of Science ®Google Scholar
• Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. Jama. 2011;305(16):1659–1668.
   PubMed Web of Science ®Google Scholar
• Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2016;66(1):180–190.
   PubMed Web of Science ®Google Scholar
• Hauck AK, Da B. Oxidative stress and lipotoxicity. J Lipid Res. 2016;57(11):1976–1986.
   PubMed Web of Science ®Google Scholar
• Alkhouri N. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol. 2009;3(4):445–451.
   PubMedGoogle Scholar
• Birkenfeld AL, Shulman GI. Non alcoholic fatty liver disease, hepatic insulin resistance and type 2 diabetes. Hepatology. 2014;59(2):713–723.
   PubMed Web of Science ®Google Scholar
• Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.
   PubMed Web of Science ®Google Scholar
• Boyraz M, Hatipoğlu N, Sarı E, et al. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obes Res Clin Pract. 2014;8(4):e356–63.
   PubMed Web of Science ®Google Scholar
• Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003;100(6):3077–3082.
   PubMed Web of Science ®Google Scholar
• Luukkonen PK, Zhou Y, Sädevirta S, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol. 2016;64(5):1167–1175.
   PubMed Web of Science ®Google Scholar
• Benedetti A, Comporti M, Esterbauer H. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochem Biophys Acta. 1980;620(2):281–296.
   PubMed Web of Science ®Google Scholar
• Lin MH, Yen JH, Weng CY, et al. Lipid peroxidation end product 4-hydroxy-trans-2-nonenal triggers unfolded protein response and heme oxygenase-1 expression in PC12 cells: roles of ROS and MAPK pathways. Toxicology. 2014;315(1):24–37.
   PubMed Web of Science ®Google Scholar
• Walenbergh SM, Shiri-Sverdlov R. Cholesterol is a significant risk factor for non-alcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2015;9(11):1343–1346.
   PubMed Web of Science ®Google Scholar
• Walenbergh SMA, Koek GH, Bieghs V, et al. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol. 2013;58(4):801–810.
   PubMed Web of Science ®Google Scholar
• van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 2011;141(4):1393–1403.
   PubMed Web of Science ®Google Scholar
• Marí M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006;4(3):185–198.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Berk M, Yerian L, et al. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci. 2014;59(7):1617–1624.
   PubMed Web of Science ®Google Scholar
• Park HS, Jang JE, Ko MS, et al. Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice. Diabetes Metab J. 2016;40(5):376–385.
   PubMed Web of Science ®Google Scholar
• Eslami L, Merat S, Malekzadeh R, et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013;12:CD008623.
   Google Scholar
• Verrijken A, Francque S, van L G. The role of visceral adipose tissue in the pathogenesis of non-alcoholic fatty liver disease. European Endocrin. 2011;7(2):96–103.
   Google Scholar
• Perry RJ, Camporez J-PG, Kursawe R, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745–758.
   PubMed Web of Science ®Google Scholar
• Sun K, Kusminski CCM, Scherer PEP. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121(6):2094–2101.
   PubMed Web of Science ®Google Scholar
• Du Plessis J, van Pelt J, Korf H, et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology. 2015;149(3):635–648.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008;32(Suppl 7):S13–S18.
   PubMed Web of Science ®Google Scholar
• Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112(1):91–100.
   PubMed Web of Science ®Google Scholar
• Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17(5):790–797.
   PubMed Web of Science ®Google Scholar
• Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131–137.
   PubMed Web of Science ®Google Scholar
• Moitra J, Mason MM, Olive M, et al. Life without white fat: A transgenic mouse. Genes Dev. 1998;12(20):3168–3181.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism. 2015;65(8):1026–1037.
   PubMed Web of Science ®Google Scholar
• Smagris E, BasuRay S, Li J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2015;61(1):108–118.
   PubMed Web of Science ®Google Scholar
• Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109(3):325–334.
   PubMed Web of Science ®Google Scholar
• Santoro N, Caprio S, Giannini C, et al. Oxidized Fatty acids: a potential pathogenic link between Fatty liver and type 2 diabetes in obese adolescents? Antioxid Redox Signal. 2014;20(2):383–389.
   PubMed Web of Science ®Google Scholar
• Davis JN, Lê KA, Walker RW, et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr. 2010;92(6):1522–1527.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Llauradó G, Orešic M, et al. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. J Hepatol. 2015;62:657–663.
   PubMed Web of Science ®Google Scholar
• Kammoun HL, Chabanon H, Hainault I, et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest. 2009;119(5):1201–1215.
   PubMed Web of Science ®Google Scholar
• Puri P, Mirshahi F, Cheung O, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134(2):568–576.
   PubMed Web of Science ®Google Scholar
• Bertola A, Bonnafous S, Anty R, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. Plos One. 2010;5(10):e13577.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140(6):900–917.
   PubMed Web of Science ®Google Scholar
• Csala M, Margittai É, Bánhegyi G. Redox control of endoplasmic reticulum function. Antioxid Redox Signal. 2009;13(1):77–108.
   Web of Science ®Google Scholar
• Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol. 2006;38(3):317–332.
   PubMed Web of Science ®Google Scholar
• Fu S, Yang L, Li P, et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature. 2011;473(7348):528–531.
   PubMed Web of Science ®Google Scholar
• Egnatchik RA, Leamy AK, Jacobson DA, et al. ER calcium release promotes mitochondrial dysfunction and hepatic cell lipotoxicity in response to palmitate overload. Mol Metab. 2014;3(5):544–553.
   PubMed Web of Science ®Google Scholar
• Park SW, Zhou Y, Lee J, et al. Sarco(endo)plasmic reticulum Ca2+-ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity. Proc Natl Acad Sci U S A. 2010;107(45):19320–19325.
   PubMed Web of Science ®Google Scholar
• H-W P, Park H, Semple IA, et al. Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers. Nat Commun. 2014;5:4834.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–812.
   PubMed Web of Science ®Google Scholar
• Bartoszewski R, Brewer JW, Rab A, et al. The Unfolded Protein Response (UPR)-activated transcription factor X-box-binding protein 1 (XBP1) induces microRNA-346 expression that targets the human antigen peptide transporter 1 (TAP1) mRNA and governs immune regulatory genes. J Biol Chem. 2011;286(48):41862–41870.
   PubMed Web of Science ®Google Scholar
• Zhang WG, Chen L, Dong Q, et al. Mmu-miR-702 functions as an anti-apoptotic mirtron by mediating ATF6 inhibition in mice. Gene. 2013;531(2):235–242.
   PubMed Web of Science ®Google Scholar
• Baffy G. MicroRNAs in nonalcoholic fatty liver disease. J Clin Med. 2015;4(12):1977–1988.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Moldoveanu T, Llambi F, et al. Family Reunion. Mol Cell. 2010;37(3):299–310.
   PubMed Web of Science ®Google Scholar
• Hetz C, Bernasconi P, Fisher J, et al. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science. 2006;312(5773):572–576.
   PubMed Web of Science ®Google Scholar
• Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell. 2009;138(5):838–854.
   PubMed Web of Science ®Google Scholar
• Leroux A, Ferrere G, Godie V, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol. 2012;57(1):141–149.
   PubMed Web of Science ®Google Scholar
• Bai Y, Onuma H, Bai X, et al. Persistent nuclear factor-kappa B activation in Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production. J Biol Chem. 2005;280(19):19062–19069.
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Wieckowska A, Lopez A, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072–1078.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet? Metabolism. 2016;65(8):1087–1095.
   PubMed Web of Science ®Google Scholar
• Serviddio G, Bellanti F, Tamborra R, et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut. 2008;57(7):957–965.
   PubMed Web of Science ®Google Scholar
• Zhou M, Xu A, Tam PKH, et al. Upregulation of UCP2 by adiponectin: the involvement of mitochondrial superoxide and hnRNP K. Plos One. 2012;7:2.
   Web of Science ®Google Scholar
• Arsenijevic D, Onuma H, Pecqueur C, et al. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet. 2000;26(4):435–439.
   PubMed Web of Science ®Google Scholar
• Han Y-H, Kim H-J, Kim E-J, et al. RORalpha decreases oxidative stress through the induction of SOD2 and GPx1 expression and thereby protects against nonalcoholic steatohepatitis in mice. Antioxid Redox Signal. 2014;21(15):2083–2094.
   PubMed Web of Science ®Google Scholar
• Walenbergh S, Houben T, Hendrikx T, et al. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation. Am J Gastroenterol. 2015;110(3):462–470.
   PubMed Web of Science ®Google Scholar
• Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91(2):1–9.
   PubMed Web of Science ®Google Scholar
• Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–185.
   PubMed Web of Science ®Google Scholar
• Rahman K, Desai C, Iyer SS, et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology. 2016;151(4):733–746.
   PubMed Web of Science ®Google Scholar
• Mazagova M, Wang L, Anfora AT, et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. Faseb J. 2015;29(3):1043–1055.
   PubMed Web of Science ®Google Scholar
• Leung C, Rivera L, Furness J, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–425.
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Ley RE. Mahowald M a, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–1031.
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–609.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965.
   PubMed Web of Science ®Google Scholar
• Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015;6:10166.
   PubMed Web of Science ®Google Scholar
• Jiang C, Xie C, Li F. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125(1):386–402.
   PubMed Web of Science ®Google Scholar
• Cani PD, Possemiers S, van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–1103.
   PubMed Web of Science ®Google Scholar
• Wree A, McGeough MD, Peña C, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med. 2014;92(10):1069–1082.
   PubMed Web of Science ®Google Scholar
• Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009;51(1):212–223.
   PubMed Web of Science ®Google Scholar
• Esposito E, Iacono A, Bianco G, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr. 2009;139(5):905–911.
   PubMed Web of Science ®Google Scholar
• Parola M, Vajro P. Nocturnal hypoxia in obese-related obstructive sleep apnea as a putative trigger of oxidative stress in pediatric NAFLD progression. J Hepatol. 2016;65(3):470–472.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Clement K, Pépin J-L. Nonalcoholic fatty liver disease and obstructive sleep apnea. Metabolism. 2016;65(8):1124–1135.
   PubMed Web of Science ®Google Scholar
• Sundaram SS, Sokol RJ, Capocelli KE, et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic Fatty liver disease. J Pediatr. 2014;164(4):699–706.
   PubMed Web of Science ®Google Scholar
• Sundaram SS, Halbower A, Pan Z, et al. Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease. J Hepatol. 2016;65(3):560–569.
   PubMed Web of Science ®Google Scholar
• Pinhas-Hamiel O, Newfield RS, Koren I, et al. Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int J Obes Relat Metab Disord. 2003;27(3):416–418.
   PubMed Web of Science ®Google Scholar
• Aeberli I, Hurrell RF, Zimmermann MB. Overweight children have higher circulating hepcidin concentrations and lower iron status but have dietary iron intakes and bioavailability comparable with normal weight children. Int J Obes (Lond). 2009;33(10):1111–1117.
   PubMed Web of Science ®Google Scholar
• Feldman A, Aigner E, Weghuber D, et al. The potential role of iron and copper in pediatric obesity and nonalcoholic fatty liver disease. Biomed Res Int. 2015;287401. DOI:10.1155/2015/287401
   PubMed Web of Science ®Google Scholar
• Manco M, Alisi A, Real JMF, et al. Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. J Hepatol. 2011;55(3):647–653.
   PubMed Web of Science ®Google Scholar
• Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010;138(3):905–912.
   PubMed Web of Science ®Google Scholar
• Aigner E, Strasser M, Haufe H, et al. A role for low hepatic copper concentrations in nonalcoholic fatty liver disease. Am J Gastroenterol. 2010;105(9):1978–1985.
   PubMed Web of Science ®Google Scholar
• Nobili V, Siotto M, Bedogni G, et al. Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2013;56(4):370–375.
   PubMed Web of Science ®Google Scholar
• Song M, Schuschke DA, Zhou Z, et al. High fructose feeding induces copper deficiency in sprague-dawley rats: A novel mechanism for obesity related fatty liver. J Hepatol. 2012;56(2):433–440.
   PubMed Web of Science ®Google Scholar